Navigation Links
Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab

Merck Pharmaceuticals from Germany and Takeda Pharmaceuticals from Japan to colloborate in marketing of Merck's cancer drug Matuzumab.

Matuzumab is developed by Merck which is in its Phase II // clinical tiral. Takeda Pharmaceuticals will sign agreement with Merck to give royalty and sale benefits from the sale of Matuzumba. Takeda will pay 60 million euros to Merck with an addition of royalty.

"Merck KGaA and Takeda Pharmaceutical have entered into a co-development and co-commercialization agreement for Merck's Matuzumab," the German company said in a statement.

Matuzumab was developed by Merck and currently is in Phase II clinical trials in patients with lung, gastric and colorectal cancers. Merck said it had decided to enter into cooperation with Takeda "in order to put more resources and expertise toward this important product". "Takedas experience and commitment in the field of oncology makes it a perfect fit with Merck, " it said.

"This collaboration with Takeda, Japans largest pharmaceutical company, will allow us to move ahead quickly with development and commercialisation of this potentially important product for cancer patients," said the head of Merck Ethical Pharmaceuticals, Elmar Schnee.

Source: Indo-Asian News Services

Page: 1

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Judgment In Favor Of Merck For Vioxx Drug
4. Merck, ICMR to conduct joint trials on cervical cancer vaccine
5. Merck in the Dock Due To Vioxx
6. Merck Says Januvia Effective In Type 2 Diabetes
7. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
8. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
9. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
10. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
11. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
Post Your Comments:

(Date:11/27/2015)... LOS ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only ... age of 30 (see Table 1-1 ). More than 3.7 billion people under ... simplex virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection ...
(Date:11/27/2015)... Karnataka (PRWEB) , ... November 27, 2015 , ... ... world, Health-E-minds, an innovative online platform for mental health and wellness consultation, has ... , This partnership will bridge the knowledge gap experienced by parents and bring ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... health and wellness consultation, has collaborated with Women’s Web – an online ... queries on topics on mental and emotional well-being relationship, life balance, stress, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... November 26, 2015 ... "Self Administration of High Viscosity Drugs" report ... has announced the addition of the "Self ... their offering. --> Research and Markets ... the "Self Administration of High Viscosity Drugs" ...
Breaking Medicine Technology: